KMDA vs. NVZMY: Which Stock Offers Greater Value?
Comparison of Stocks: Kamada (KMDA) has a Zacks Rank of #2 (Buy) indicating a strong earnings outlook, while Novozymes A/S (NVZMY) holds a Zacks Rank of #3 (Hold), suggesting a less favorable analyst outlook for investors.
Valuation Metrics: KMDA's forward P/E ratio is 17.34 and PEG ratio is 0.69, indicating it may be undervalued compared to NVZMY, which has a forward P/E of 25.80 and a PEG ratio of 1.16.
Value Grades: Based on various valuation metrics, KMDA has earned a Value grade of A, while NVZMY has a Value grade of D, highlighting KMDA as the superior value option.
Investment Recommendation: The article suggests that value investors may find better opportunities in Kamada due to its improving earnings outlook and favorable valuation metrics compared to Novozymes.
Trade with 70% Backtested Accuracy
Analyst Views on KMDA
About KMDA
About the author

- Earnings Announcement: Kamada is set to release its Q4 earnings on March 11 before market open, with a consensus EPS estimate of $0.08, reflecting a 14.3% year-over-year increase, indicating ongoing improvements in profitability that may attract investor interest.
- Revenue Expectations: Analysts forecast Kamada's Q4 revenue to reach $46.62 million, representing a 19.5% year-over-year growth, which underscores the company's strong performance in market demand and product sales, potentially laying the groundwork for future expansion.
- Historical Performance: Over the past two years, Kamada has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, suggesting a consistent ability to exceed market expectations, which may bolster confidence in its future performance.
- Future Outlook: Kamada anticipates achieving double-digit profitable growth by 2026, a projection that not only reflects the company's confidence in future market opportunities but also may attract long-term investors, further driving stock price appreciation.
- Dividend Announcement: Kamada declares a cash dividend of $0.25 per share, payable on April 6, with a record date of March 23 and an ex-dividend date also on March 23, demonstrating the company's commitment to shareholder returns.
- Profit Growth Forecast: Kamada anticipates achieving double-digit profitable growth by 2026, indicating that the company is likely to drive revenue growth through new products and market expansion, thereby enhancing investor confidence.
- Quant Rating: Seeking Alpha's Quant Rating on Kamada reflects positive market sentiment, showcasing analysts' optimistic outlook on the company's future performance, which may attract more investor interest.
- Historical Financial Data: Kamada's historical earnings data provides investors with crucial financial context to assess the company's long-term performance and future growth potential, further supporting its shareholder return strategy.
- Significant Revenue Growth: Kamada Ltd. reported revenues of $180.5 million for 2025, a 12% year-over-year increase, indicating strong market performance that is expected to bolster investor confidence.
- Substantial Net Income Increase: The net income for 2025 reached $20.2 million, a 40% rise from 2024, reflecting successful strategies in cost control and revenue growth, thereby enhancing financial stability.
- Cash Dividend Policy: The company declared a cash dividend of $0.25 per share, totaling approximately $14.4 million, demonstrating management's confidence in future cash flows and growth prospects, likely attracting more investor interest.
- Optimistic 2026 Outlook: Management reaffirmed guidance for 2026 revenues of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, showcasing the company's ongoing potential in organic growth and new business development.
- Earnings Performance: Kamada reported Q4 GAAP EPS of $0.06, missing expectations by $0.02, indicating pressure on profitability that may affect investor confidence moving forward.
- Revenue Growth Lags: The Q4 revenue of $44.68 million, while up 14.6% year-over-year, fell short of expectations by $1.94 million, reflecting unmet market demand that could impact future strategic decisions.
- 2026 Performance Outlook: Kamada affirms its 2026 revenue guidance of $200 million to $205 million, which is close to the $204.97 million consensus but only represents a 13% growth, highlighting challenges in achieving robust growth.
- Adjusted EBITDA Guidance: The company anticipates adjusted EBITDA between $50 million and $53 million for 2026, representing a 23% increase compared to 2025 results, although market confidence in its profitability may be affected.

Report Overview: Recent reports from investment and research firms provide insights into analysts' perspectives on various companies.
Disclaimer: The views expressed in these reports do not reflect the opinions or recommendations of Barron’s.
Investment Services: Some report issuers may have existing or potential investment-banking relationships with the companies analyzed.
Purpose of Reports: The reports serve as a sampling of analyst thinking rather than definitive investment advice.
- 2026 Financial Outlook: Kamada projects revenues of $200 million to $205 million for 2026, representing a 13% year-over-year increase based on the midpoint of 2025 guidance, highlighting the company's ongoing organic growth potential across its diverse product portfolio in the biopharmaceutical sector.
- Adjusted EBITDA Growth: The company anticipates adjusted EBITDA to reach $50 million to $53 million in 2026, reflecting a 23% increase from the midpoint of 2025, which signifies a substantial enhancement in profitability and boosts investor confidence.
- Strong Cash Position: Kamada expects to end 2025 with approximately $75 million in cash, ensuring financial flexibility for future investments and business expansions, thereby strengthening its competitive edge in global markets.
- Strategic Development Focus: The company will continue to prioritize new business development and M&A transactions to accelerate long-term profitable growth, a strategy that will enrich its marketed product portfolio and generate synergies with existing operations.








